Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting. Issue 1 (23rd September 2022)

• Record Type: Journal Article
• Authors: Gambardella, Alessio; Licata, Gaetano; De Rosa, Alina; Calabrese, Giulia; Alfano, Roberto; Argenziano, Giuseppe
• Is Part Of: JEADV clinical practice. Volume 2:Issue 1(2023)
• Page Start: 52
• Page End: 58
• Publication Date: 2022-09-23
• Subjects: biological drugs -- DLQI -- PASI -- plaque psoriasis -- quality of life -- real life -- tildrakizumab; Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1002/jvc2.65
• Languages: English
• ISSNs: 2768-6566

Abstract

Abstract: Background: Information is lacking from real‐life studies evaluating the efficacy of tildrakizumab in moderate‐to‐severe psoriasis. Materials and Methods: We retrospectively analysed a database of 30 patients with moderate‐to‐severe psoriasis (PsO) that were treated with tildrakizumab (100 mg, s.c.) and followed for 36 weeks. Clinical efficacy (disease severity and treatment response) was evaluated by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, and 36 weeks. The quality of life (QoL) of PsO patients was measured using the Dermatology Life Quality Index (DLQI). Results: A PASI score of <3 was achieved after 12, 24, and 36 weeks in 86.7%, 100%, and 100% patients, respectively (aged 46.3 ± 13.3 years) treated with tildrakizumab. PASI score significantly decreased from 17.6 ± 4.7 at baseline to 4.7 ± 4.7 and 1.1 ± 3.9 at 4 and 12 weeks remaining <1 up to 36 weeks ( p < 0.001 vs. baseline), and PASI −75–90 and −100 response was achieved in 100%, 96.7%, and 60% of patients respectively at 36 weeks. DLQI also significantly decreased from baseline (13.8 ± 2.9) to 3.6 ± 1.6 at 4 weeks, 1.4 ± 0.6 at 12 weeks and 0 at Week 24 and 36 ( p < 0.001 vs. baseline). Multivariate regression revealed that the effect of tildrakizumab on PASI score or DLQI at 4 weeks was independent from the predictor variables age, gender, BMI, disease duration, previous biologic, or presence of comorbidities. No adverse event was reported during treatment with tildrakizumab. Conclusion: This retrospective study shows that patients with moderate‐to‐severe PsO treated with tildrakizumab in the real world‐setting was effective and safe up to 36 weeks.